Scholar Rock Holding (SRRK) Research & Development (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Research & Development of $51.8 million in Q1 2026, up 10.54% quarter-over-quarter from $46.9 million in Q4 2025, and up 6.44% on a YoY basis from $48.7 million in Q1 2025.
Scholar Rock Holding (SRRK) Research & Development (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Research & Development history runs 10 years deep, the most recent figure standing at $51.8 million for Q1 2026.
- In Q1 2026, Research & Development rose 6.44% year-over-year to $51.8 million; the TTM figure through Mar 2026 stood at $211.6 million (up 11.28% YoY), while the FY2025 annual figure was $208.4 million, up 12.95% from the prior year.
- Research & Development was $51.8 million for Q1 2026 at Scholar Rock Holding, up from $46.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $62.4 million in Q2 2025 to a low of $26.9 million in Q2 2023.
- Historically, Research & Development has averaged $40.7 million across 5 years, with a median of $42.4 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Research & Development retreated 16.23% in 2023, then jumped 60.59% in 2024.
- A 5-year view of Research & Development shows it stood at $29.6 million in 2022, then gained by 18.06% to $35.0 million in 2023, then soared by 44.06% to $50.4 million in 2024, then fell by 6.93% to $46.9 million in 2025, then climbed by 10.54% to $51.8 million in 2026.
- The last three Research & Development figures came in at $51.8 million (Q1 2026), $46.9 million (Q4 2025), and $50.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | 51.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.81 Mn |
| Dec 31, 2025 | 46.88 Mn |
| Sep 30, 2025 | 50.49 Mn |
| Jun 30, 2025 | 62.40 Mn |
| Mar 31, 2025 | 48.68 Mn |
| Dec 31, 2024 | 50.37 Mn |
| Sep 30, 2024 | 48.72 Mn |
| Jun 30, 2024 | 42.37 Mn |
| Mar 31, 2024 | 43.09 Mn |
| Dec 31, 2023 | 34.96 Mn |
| Sep 30, 2023 | 30.34 Mn |
| Jun 30, 2023 | 26.87 Mn |
| Mar 31, 2023 | 29.74 Mn |
| Dec 31, 2022 | 29.61 Mn |
| Sep 30, 2022 | 33.39 Mn |
| Jun 30, 2022 | 32.07 Mn |
| Mar 31, 2022 | 29.37 Mn |
| Dec 31, 2021 | 29.05 Mn |
| Sep 30, 2021 | 31.27 Mn |
| Jun 30, 2021 | 25.60 Mn |